Alzheimer’s drug slows cognitive decline by 35, says manufacturer

摘要

In a statement published on 3 May 2023 (https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional) , Lilly said that its trial results showed that donanemab — an experimental amyloid plaque targeting therapy administered by IV drip — “significantly slowed cognitive and functional decline” in 1,182 people with early symptomatic Alzheimer’s disease (AD).